tetano
Editor, Senior Moderator
J Biomol Struct Dyn
. 2022 Aug 23;1-14.
doi: 10.1080/07391102.2022.2112080. Online ahead of print.
Discovery of novel potential inhibitors of TMPRSS2 and Mpro of SARS-CoV-2 using E-pharmacophore and docking-based virtual screening combined with molecular dynamic and quantum mechanics
Mohanad A Mahgoub[SUP] 1 [/SUP], Ahmed Alnaem[SUP] 1 [/SUP], Mohammed Fadlelmola[SUP] 1 [/SUP], Mazin Abo-Idris[SUP] 1 [/SUP], Alaa A Makki[SUP] 1 [/SUP], Abdelgadir A Abdelgadir[SUP] 2 [/SUP], Abdulrahim A Alzain[SUP] 1 [/SUP]
Affiliations
Abstract
The pandemic of coronavirus disease is caused by the SARS-CoV-2 which is considered a global health issue. The main protease of COVID 19 (Mpro) has an important role in viral multiplication in the host cell. Inhibiting Mpro is a novel approach to drug discovery and development. Also, transmembrane serine proteases (TMPSS2) facilitate viral activation by cleavage S glycoproteins, thus considered one of the essential host factors for COVID-19 pathogenicity. Computational tools were widely used to reduce time and costs in search of effective inhibitors. A chemical library that contains over two million molecules was virtually screened against TMPRSS2. Also, XP docking for the top hits was screened against (Mpro) to identify dual-target inhibitors. Furthermore, MM-GBSA and predictive ADMET were performed. The top hits were further studied through density functional theory (DFT) calculation and showed good binding to the active sites. Moreover, molecular dynamics (MD) for the top hits were performed which gave information about the stability of the protein-ligand complex during the simulation period. This study has led to the discovery of potential dual-target inhibitors Z751959696, Z751954014, and Z56784282 for COVID-19 with acceptable pharmacokinetic properties. The outcome of this study can participate in the development of novel inhibitors to defeat SARS-CoV-2.Communicated by Ramaswamy H. Sarma.
Keywords: E-pharmacophore mapping and screening; Molecular docking; Mpro; SARS-CoV-2; TMPRSS2.
. 2022 Aug 23;1-14.
doi: 10.1080/07391102.2022.2112080. Online ahead of print.
Discovery of novel potential inhibitors of TMPRSS2 and Mpro of SARS-CoV-2 using E-pharmacophore and docking-based virtual screening combined with molecular dynamic and quantum mechanics
Mohanad A Mahgoub[SUP] 1 [/SUP], Ahmed Alnaem[SUP] 1 [/SUP], Mohammed Fadlelmola[SUP] 1 [/SUP], Mazin Abo-Idris[SUP] 1 [/SUP], Alaa A Makki[SUP] 1 [/SUP], Abdelgadir A Abdelgadir[SUP] 2 [/SUP], Abdulrahim A Alzain[SUP] 1 [/SUP]
Affiliations
- PMID: 35997154
- DOI: 10.1080/07391102.2022.2112080
Abstract
The pandemic of coronavirus disease is caused by the SARS-CoV-2 which is considered a global health issue. The main protease of COVID 19 (Mpro) has an important role in viral multiplication in the host cell. Inhibiting Mpro is a novel approach to drug discovery and development. Also, transmembrane serine proteases (TMPSS2) facilitate viral activation by cleavage S glycoproteins, thus considered one of the essential host factors for COVID-19 pathogenicity. Computational tools were widely used to reduce time and costs in search of effective inhibitors. A chemical library that contains over two million molecules was virtually screened against TMPRSS2. Also, XP docking for the top hits was screened against (Mpro) to identify dual-target inhibitors. Furthermore, MM-GBSA and predictive ADMET were performed. The top hits were further studied through density functional theory (DFT) calculation and showed good binding to the active sites. Moreover, molecular dynamics (MD) for the top hits were performed which gave information about the stability of the protein-ligand complex during the simulation period. This study has led to the discovery of potential dual-target inhibitors Z751959696, Z751954014, and Z56784282 for COVID-19 with acceptable pharmacokinetic properties. The outcome of this study can participate in the development of novel inhibitors to defeat SARS-CoV-2.Communicated by Ramaswamy H. Sarma.
Keywords: E-pharmacophore mapping and screening; Molecular docking; Mpro; SARS-CoV-2; TMPRSS2.